Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

(2009) Elizabeth Poplin et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

(2009) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidemiology of pancreatic cancer: an overview

(2009) Sara Raimondi et al.   Nature Reviews Gastroenterology & Hepatology

Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies

(2008) B. R. Tan et al.   ANNALS OF ONCOLOGY

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

(2008) Volker Heinemann et al.   BMC CANCER

Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001

(2008) Jürg Bernhard et al.   JOURNAL OF CLINICAL ONCOLOGY

Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients

(2008) Eva Gross et al.   PLoS One